Skip to Content
Merck
  • IL-1 receptor blockade alleviates endotoxin-mediated impairment of renal drug excretory functions in rats.

IL-1 receptor blockade alleviates endotoxin-mediated impairment of renal drug excretory functions in rats.

American journal of physiology. Renal physiology (2014-12-17)
Zuzana Kadova, Eva Dolezelova, Jolana Cermanova, Milos Hroch, Tomas Laho, Lucie Muchova, Frantisek Staud, Libor Vitek, Jaroslav Mokry, Jaroslav Chladek, Zuzana Havlinova, Milan Holecek, Stanislav Micuda
ABSTRACT

The aim of our study was to investigate whether two potent anti-inflammatory agents, dexamethasone and anakinra, an IL-1 receptor antagonist, may influence acute kidney injury (AKI) and associated drug excretory functions during endotoxemia (LPS) in rats. Ten hours after LPS administration, untreated endotoxemic rats developed typical symptoms of AKI, with reduced GFR, impaired tubular excretion of urea and sodium, and decreased urinary excretion of azithromycin, an anionic substrate for multidrug resistance-transporting proteins. Administration of both immunosuppressants attenuated the inflammatory response, liver damage, AKI, and increased renal clearance of azithromycin mainly by restoration of GFR, without significant influence on its tubular secretion. The lack of such an effect was related to the differential effect of both agents on the renal expression of individual drug transporters. Only dexamethasone increased the urinary clearance of bile acids, in accordance with the reduction of the apical transporter (Asbt) for their tubular reabsorption. In summary, our data demonstrated the potency of both agents used for the prevention of AKI, imposed by endotoxins, and for the restoration of renal drug elimination, mainly by the improvement of GFR. The influence of both drugs on altered tubular functions and the expression of drug transporters was differential, emphasizing the necessity of knowledge of transporting pathways for individual drugs applied during sepsis. The effect of anakinra suggests a significant contribution of IL-1 signaling to the pathogenesis of LPS-induced AKI.

MATERIALS
Product Number
Brand
Product Description

Supelco
Dexamethasone, VETRANAL®, analytical standard
Sigma-Aldrich
Dexamethasone, tested according to Ph. Eur.
Sigma-Aldrich
Monoclonal Anti-P-Glycoprotein (MDR) antibody produced in mouse, clone F4, ascites fluid
Sigma-Aldrich
Dexamethasone, meets USP testing specifications
Sigma-Aldrich
Dexamethasone, powder, BioReagent, suitable for cell culture, ≥97%
Sigma-Aldrich
Dexamethasone, powder, γ-irradiated, BioXtra, suitable for cell culture, ≥80% (HPLC)
Sigma-Aldrich
Anti-Heme Oxygenase-1 antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution
Sigma-Aldrich
Dexamethasone, ≥98% (HPLC), powder
Sigma-Aldrich
Anti-SLC22A7 (AB1) antibody produced in rabbit, affinity isolated antibody
USP
Azithromycin Identity, United States Pharmacopeia (USP) Reference Standard
Dexamethasone for peak identification, European Pharmacopoeia (EP) Reference Standard
Azithromycin for peak identification, European Pharmacopoeia (EP) Reference Standard
Azithromycin, European Pharmacopoeia (EP) Reference Standard
USP
Azithromycin, United States Pharmacopeia (USP) Reference Standard
Azithromycin for system suitability, European Pharmacopoeia (EP) Reference Standard
Zidovudine, European Pharmacopoeia (EP) Reference Standard
Dexamethasone, European Pharmacopoeia (EP) Reference Standard
Dexamethasone, British Pharmacopoeia (BP) Assay Standard
USP
Dexamethasone, United States Pharmacopeia (USP) Reference Standard
USP
Zidovudine, United States Pharmacopeia (USP) Reference Standard
Supelco
Zidovudine, Pharmaceutical Secondary Standard; Certified Reference Material
Dexamethasone for system suitability, European Pharmacopoeia (EP) Reference Standard
Supelco
Dexamethasone, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
3′-Azido-3′-deoxythymidine, ≥98% (HPLC)